Posted by Michael Wonder on 30 Oct 2018
Institute for Clinical and Economic Review to publish upcoming assessment on treatments for peanut allergy
30 October 2018 - Report will be subject of CTAF meeting in June 2019; open input now being accepted until 15 November 2018.
ICER announced today that it plans to assess the comparative clinical effectiveness and value of potential new treatments for peanut allergy. The report will be reviewed during a public meeting of the California Technology Assessment Forum in June of 2019.
ICER's assessment will focus on Viaskin Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics). Viaskin Peanut is currently undergoing FDA review with an approval decision expected in the middle of 2019. For AR101, Aimmune has announced its intention to submit a biologics license application with the FDA by the end of 2018.
